Last reviewed · How we verify
Cerebrolysin infusion — Competitive Intelligence Brief
marketed
Neuropeptide mixture
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cerebrolysin infusion (Cerebrolysin infusion) — Clinical Institute of the Brain, Russia. Cerebrolysin is a standardized peptide and amino acid mixture derived from porcine brain that promotes neuroprotection and neuroplasticity through multiple mechanisms including neurotrophic factor activity and metabolic support.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cerebrolysin infusion TARGET | Cerebrolysin infusion | Clinical Institute of the Brain, Russia | marketed | Neuropeptide mixture |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Neuropeptide mixture class)
- Clinical Institute of the Brain, Russia · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cerebrolysin infusion CI watch — RSS
- Cerebrolysin infusion CI watch — Atom
- Cerebrolysin infusion CI watch — JSON
- Cerebrolysin infusion alone — RSS
- Whole Neuropeptide mixture class — RSS
Cite this brief
Drug Landscape (2026). Cerebrolysin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/cerebrolysin-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab